FRANCE – Eligo Bioscience, a Paris, France-based gene-editing company, raised $30M in Series B funding.
The round was led by Sanofi Ventures with participation from new investor Bpifrance (through its InnoBio 2 fund), and existing investors Khosla Ventures and Seventure Partners. Concurrent with this financing, Laia Crespo, Ph.D., Partner at Sanofi Ventures and Benoit Barteau, Investment Director at Bpifrance, will join the board of directors.This funding is earmarked for accelerating the development of Eligo’s flagship program, EB005, which targets moderate to severe acne vulgaris, an inflammatory disease that affects about 3% of the global population. The investment will fuel pre-IND and IND activities to achieve early human data readouts in a Ph1b/2a clinical trial. Additionally, it will facilitate Eligo’s expansion into other chronic diseases, including oncology.Founded by Luciano Marraffini (Professor at The Rockefeller University and cofounder of Intellia Therapeutics, Timothy Lu (Professor at MIT, and CEO at Senti Biosciences), Dr. David Bikard (Professor at Institut Pasteur) and CEO Xavier Duportet, Eligo Bioscience is a company which specializes in microbiome in-vivo gene editing and is advancing a highly differentiated pipeline of precision medicines to address unmet medical needs in immuno-inflammation, oncology, and infectious diseases driven by the expression of deleterious bacterial genes.05/12/2023
